All Oncology News

ICT01 has received FDA breakthrough therapy designation as frontline therapy for patients with AML who are unfit for induction chemotherapy.

Treatment with pembrolizumab after GI-6207 therapy did not generate therapeutic responses in patients with recurrent/metastatic medullary thyroid cancer.

Nemtabrutinib plus venetoclax showed early activity and manageable safety in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

The AACN's Beacon Award for Excellence has been awarded to Roswell Park Comprehensive Cancer Center's Intensive Care Unit.

The autologous tumor-cell immunotherapy improved OS and RFS vs placebo in patients who achieved a CR after undergoing surgery and frontline chemotherapy.

Teclistamab monotherapy significantly improved PFS and OS vs standard-of-care therapy in relapsed/refractory multiple myeloma as early as the second line.

Yue Wei, PhD, discussed the role of HMAs in platelet response in MDS and the clinical relevance of using a mouse model to investigate this approach.

Experts reflect on pivotal data from the 2026 Gastrointestinal Cancers Symposium that are set to change practice in HCC, CRC, and other GI cancers.

SCIB1/iSCIB1+ plus ipilimumab and nivolumab displayed T-cell responses in treatment-naive, unresectable melanoma.

Updated data from the GOBLET trial show pelareorep plus atezolizumab achieved a 29% ORR with durable responses in heavily pretreated SCAC.

Andrea Necchi, MD, dives into the details of the SunRISe-4 trial findings, implications, and ways that utDNA and ctDNA may operate as biomarkers in MIBC.

Mark A. Socinski, MD, and Martin F. Dietrich, MD, PhD, discuss molecular testing methodologies for NSCLC.

Nogapendekin alfa inbakicept plus an immune checkpoint inhibitor generated absolute lymphocyte count increases in non–small cell lung cancer.

The expansion of WVU Medicine hospitals across the state is changing how and where patients, including those with cancer, receive care.

David P. Carbone, MD, PhD, and Niels Reinmuth, MD, PhD, discussed the landscapes of biomarker testing and screening in NSCLC.

Andrew W. Hahn, MD, discusses the efficacy and safety of lenvatinib plus everolimus in metastatic ccRCC after progression on PD-1–directed ICIs

Treatment discontinuation with first-line BTK inhibitors was higher in the real-world setting vs the clinical trial setting among patients with CLL/SLL.

Jessica C. Hassel, MD, discusses the mechanism of action of the IO102-IO103 vaccine and the implications of its efficacy data in melanoma.

Virginia Kaklamani, MD, discusses data from the ELEVATE study of elacestrant as a combination component in ER+/HER2- breast cancer.

A study led by UC San Francisco researchers found that anti-LAG-3/anti-PD-1 combination therapy shows a higher risk of myocarditis vs other ICI treatments.

The FDA has accepted an NDA for pimicotinib in tenosynovial giant cell tumor, supported by data from the phase 3 MANEUVER trial.

A target action date of August 30, 2026, has been set for the FDA's decision regarding the sBLA seeking the approval of ropeginterferon alfa-2b for ET.

LY4170156 was well tolerated and generated promising efficacy data in patients with recurrent, platinum- resistant high-grade serous ovarian cancer.

Patients with relapsed/refractory MCL had poor treatment outcomes with BTK inhibition, which decreased in quality as the line of therapy advanced.

The addition of mFOLFOX6 and bevacizumab to atezolizumab improved PFS compared with atezolizumab monotherapy in dMMR/MSI-H mCRC.

Encorafenib plus cetuximab and FOLFIRI significantly improved response vs standard therapy in first-line BRAF V600E–mutant metastatic colorectal cancer.

Penipulimab plus anlotinib and chemotherapy showed improved efficacy compared with chemotherapy alone in treatment-naïve metastatic pancreatic cancer.

Nivolumab plus ipilimumab continued to yield an efficacy and safety benefit vs lenvatinib or sorafenib in previously untreated, unresectable HCC.

An international group of thoracic oncology specialists reviewed key updates in first-line NSCLC from the 2025 ESMO Asia Congress.

MedEduChat, an EHR-integrated AI agent provided individualized prostate cancer education for patients according to researchers at Mayo Clinic.